Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2005
Intratympanic steroid injection for treatment of idiopathic sudden hearing loss.
Клиническое исследованиеСравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Slattery William H, Fisher Laurel M, Iqbal Zarina, Friedman Rick A, Liu Nancy
Аннотация
OBJECTIVE: To conduct a clinical trial of intratympanic steroid injection for idiopathic sudden sensorineural hearing loss in subjects who failed oral steroid therapy.
STUDY DESIGN AND SETTING: Open-label methylprednisolone injection clinical trial in a tertiary neurotologic referral center. Twenty subjects (14 males; 6 females) received 4 injections within a 2-week period (4 days apart). Hearing, dizziness, and tinnitus were evaluated before and after treatment.
RESULTS: There were no serious unexpected adverse events and 2 types of expected adverse events (tympanic membrane perforation, nausea after injection). No increases in dizziness or tinnitus lasting longer than 24 hours were observed after injections. One of 20 (5%) improved to near-normal hearing. In addition, there was statistically significant improvement in 4-frequency pure-tone average and speech discrimination score at 1 month after treatment.
CONCLUSION: Four intratympanic injections of methylprednisolone improved pure-tone average or speech discrimination scores for a subset of sudden hearing loss subjects that failed to benefit from oral steroids.
SIGNIFICANCE: A clinical trial of intratympanic injections for idiopathic sudden hearing loss was successfully completed and promising results were found.
STUDY DESIGN AND SETTING: Open-label methylprednisolone injection clinical trial in a tertiary neurotologic referral center. Twenty subjects (14 males; 6 females) received 4 injections within a 2-week period (4 days apart). Hearing, dizziness, and tinnitus were evaluated before and after treatment.
RESULTS: There were no serious unexpected adverse events and 2 types of expected adverse events (tympanic membrane perforation, nausea after injection). No increases in dizziness or tinnitus lasting longer than 24 hours were observed after injections. One of 20 (5%) improved to near-normal hearing. In addition, there was statistically significant improvement in 4-frequency pure-tone average and speech discrimination score at 1 month after treatment.
CONCLUSION: Four intratympanic injections of methylprednisolone improved pure-tone average or speech discrimination scores for a subset of sudden hearing loss subjects that failed to benefit from oral steroids.
SIGNIFICANCE: A clinical trial of intratympanic injections for idiopathic sudden hearing loss was successfully completed and promising results were found.
Предметные рубрики MeSH
AdultAge FactorsAgedAged, 80 and overAudiometry, Pure-ToneDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHearing Loss, SuddenHumansInjections, IntralesionalMaleMethylprednisoloneMiddle AgedProbabilityProspective StudiesRecovery of FunctionRisk AssessmentSeverity of Illness IndexSex FactorsTreatment OutcomeTympanic Membrane